| Company Name: |
Shanghai Boyle Chemical Co., Ltd.
|
| Tel: |
021-50182298 021-50180596 |
| Email: |
sales@boylechem.com |
| Products Intro: |
Product Name:3-Phenyl-2-thioxo-1,2,3,4-tetrahydroquinazolin
CAS:18741-24-7
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Tel: |
18210857532; 18210857532 |
| Email: |
jkinfo@jkchemical.com |
| Products Intro: |
Product Name:3-Phenyl-2-thioxo-2,3-dihydro-4(1H)-quinazolinone
CAS:18741-24-7
Purity:>95% Package:1g, 5g, 500mg
|
3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE manufacturers
- PDE7 inhibitor S14
-
- $2500.00 / 100mg
-
2026-01-04
- CAS:18741-24-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE Basic information |
| Product Name: | 3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE | | Synonyms: | 3-phenyl-2-sulfanylidene-1H-quinazolin-4-one;3-phenyl-2-thioxo-1H-quinazolin-4-one;3-Phenyl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one;Quinazolin-4-one, 1,3-dihydro-3-phenyl-2-thio-;4(1H)-Quinazolinone,2,3-dihydro-3-phenyl-2-thioxo-;TIMTEC-BB SBB000936;1,3-dihydro-3-phenyl-2-thio-quinazolin-4-on;3-PHENYL-2-THIOXO-2,3-DIHYDRO-4(1H)-QUINAZOLINONE | | CAS: | 18741-24-7 | | MF: | C14H10N2OS | | MW: | 254.31 | | EINECS: | 242-550-6 | | Product Categories: | quinazolinone | | Mol File: | 18741-24-7.mol |  |
| | 3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE Chemical Properties |
| Melting point | 313-314°C | | Boiling point | 414.8±28.0 °C(Predicted) | | density | 1.40±0.1 g/cm3(Predicted) | | pka | 10.96±0.20(Predicted) |
| Hazard Codes | Xi | | HazardClass | IRRITANT | | HS Code | 2933998090 | | Toxicity | mouse,LD50,intravenous,180mg/kg (180mg/kg),U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#04508, |
| | 3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE Usage And Synthesis |
| Uses | PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases[1]. | | References | [1] Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles DOI:10.3390/ijms22063206 |
| | 3-PHENYL-2-THIOXO-1,2,3,4-TETRAHYDROQUINAZOLIN-4-ONE Preparation Products And Raw materials |
|